Park Kwonoh, Jun Hyun Jung, Oh So Yeon
Department of Hematology-Oncology, KEPCO Medical Center, Seoul, South Korea.
Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, South Korea.
Support Care Cancer. 2016 Dec;24(12):4987-4992. doi: 10.1007/s00520-016-3360-6. Epub 2016 Jul 26.
The purpose of this study was to investigate the safety, efficacy, and subjective satisfaction of peripherally inserted central catheters (PICCs) in terminally ill cancer patients.
All PICCs were inserted by an interventional radiologist with radiological guidance. We monitored the occurrence of PICC-related complication and evaluated the patient-perceived satisfaction for PICC using semi-structured questionnaire.
A total of 36 terminally ill cancer patients underwent PICC. Three patients had 2 PICC insertions; hence, finally 39 episodes during 829 PICC days were analyzed. All procedures were completed without any procedure-related complication. The median catheter life span was 19.0 days (95 % CI, 14.1-23.9). Thirty-four cases maintained the PICC until the intended time, while the other 5 cases (12.8 %; 6.1/1000 PICC days) were premature PICC removals. Totally 10 complications (25.6 %; 12.3/1000 PICC days) were reported including premature removals (n = 5), trivial bleedings (n = 3), and thrombophlebitis (n = 2). Patients reported that the procedure was not distressing (42 %), a little distressing (36 %), or distressing (21 %). Of 30 patients who had preserved cognitive function at fifth day, most patients (n = 25, 83 %) reported more comfort although the other 5 patients reported no change (n = 3) or less comfort (n = 2).
PICCs were safely inserted and showed favorable maintenance rate with acceptable complications. Additionally, most of the patients felt that parenteral access became much comfortable after PICC insertion. When considering the characteristics of terminally ill cancer patients, poor general condition and a limited period of survival, PICC could be a safe and effective method for intravenous access.
本研究旨在调查外周静脉穿刺中心静脉导管(PICC)在晚期癌症患者中的安全性、有效性和主观满意度。
所有PICC均由介入放射科医生在放射学引导下插入。我们监测PICC相关并发症的发生情况,并使用半结构化问卷评估患者对PICC的满意度。
共有36例晚期癌症患者接受了PICC置管。3例患者进行了2次PICC置管;因此,最终对829个PICC日中的39次置管情况进行了分析。所有操作均顺利完成,未出现任何与操作相关的并发症。导管中位留置时间为19.0天(95%CI,14.1 - 23.9)。34例患者的PICC留置至预期时间,另外5例(12.8%;6.1/1000 PICC日)提前拔除PICC。共报告了10例并发症(25.6%;12.3/1000 PICC日),包括提前拔除(n = 5)、轻微出血(n = 3)和血栓性静脉炎(n = 2)。患者报告该操作无痛苦(42%)、有一点痛苦(36%)或痛苦(21%)。在第5天仍保留认知功能的30例患者中,大多数患者(n = 25,83%)表示舒适度增加,尽管另外5例患者报告无变化(n = 3)或舒适度降低(n = 2)。
PICC置管安全,留置率良好,并发症可接受。此外,大多数患者认为置管后肠外通路舒适度明显提高。考虑到晚期癌症患者的特点、一般状况差和生存期有限,PICC可能是一种安全有效的静脉通路方法。